Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients (Q24321975)

lipoprotein metabolic process

GOA release 2020-03-11

1 reference

GOA release 2020-03-11

1 reference

Livia Pisciotta

1

0 references

Tommaso Fasano

2

0 references

Antonella Bellocchio

3

0 references

Letizia Bocchi

4

0 references

Raffaella Sallo

5

0 references

Raffaele Fresa

6

0 references

Isabella Colangeli

7

0 references

Alfredo Cantafora

8

0 references

Sebastiano Calandra

9

0 references

Stefano Bertolini

Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia

10

0 references

language of work or name

English

0 references

publication date

October 2007

0 references

published in

Atherosclerosis

0 references

volume

194

0 references

issue

2

0 references

page(s)

e116-22

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Why some patients respond poorly to statins and how this might be remedied

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Localization and role of NPC1L1 in cholesterol absorption in human intestine

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021

Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.10.036

7 January 2021